Summary : Third approved indication for SKYRIZI (risankizumab-rzaa) is supported by safety and efficacy data…
Tag:
AbbVie
-
-
Global Market
AbbVie, Eli Lilly, Novartis and more cut back in Russia amid corporate exodus over Ukraine war
by adminSummary : Since the invasion of Ukraine, hundreds of companies have announced a pause or…
-
Summary : AbbVie has bolstered its neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based…
-
Summary : Chicago-based AbbVie has been making major decisions with company-wide impacts. The therapeutic company…
-
AbbVieChemIntelligenceGlobal Market
VUITY™ (pilocarpine HCI Ophthalmic solution) 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry Near Vision (Presbyopia), is Now Available
by adminHighlights – Presbyopia, or age-related blurry near vision, is a common, progressive condition that reduces…
-
ChemIntelligenceU.S FDA
Intra-Cellular gets another FDA Nod for Caplyta, this time for Bipolar Disorder
by adminSynopsis: CAPLYTA is the only FDA-approved treatment for depressive episodes associated with bipolar I or…
-
Synopsis: AbbVie’s blockbuster hopeful Rinvoq notched a win in a tricky-to-treat group of Crohn’s disease…
-
Active Pharmaceutical Ingredients (API)Risankizumab
European Commission approves AbbVie’s Skyrizi (Risankizumab) to Treat Adults with Active Psoriatic Arthritis.
by adminKEYPOINTS: AbbVie announces that the European Commission (EC) has approved SKYRIZI (Risankizumab, 150 mg, subcutaneous…